Meeting
2019 ASCO Annual Meeting
Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM).
Authors
Daniel Ying Wang
Baylor College of Medicine, Houston, TX
Daniel Ying Wang , Carina N. Owen , David James Palmieri , Justine Vanessa Cohen , Zeynep Eroglu , Georgina V. Long , Ryan J. Sullivan , Justin M. Balko , Matteo S. Carlino , Alexander M. Menzies , Douglas Buckner Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9564)
DOI
10.1200/JCO.2019.37.15_suppl.9564
Abstract #
9564
Poster Bd #
135
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin
Poster
2023 ASCO Annual Meeting
Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.
First Author: Lili Mao
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2024 ASCO Annual Meeting
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
First Author: Charlee Nardin